Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.

ABSTRACT:

Aim

To estimate the cost-effectiveness of sequential addition of empagliflozin versus sitagliptin after metformin in patients with type 2 diabetes (T2D) with or without cardiovascular disease (CVD) from the perspective of the US healthcare payer.

Methods

An individual simulation model predicted lifetime diabetes-related complications, using UKPDS-OM2 equations in patients without CVD, and EMPA-REG OUTCOME equations in patients with CVD. Additional US-based sources informed inputs for population characteristics, adverse events, non-CV death, treatment escalation, quality of life and costs. Costs and quality-adjusted life-years (QALYs) were discounted 3.0% annually.

Results

The incremental cost-effectiveness ratio (ICER) for second-line empagliflozin versus sitagliptin

SUBMITTER: Reifsnider O 

PROVIDER: S-EPMC7898389 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature